Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI)
- 3 May 2022
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 158 (3) , 349-357
Abstract
Purpose Social determinants of health (SDoH)—socioeconomic and environmental factors—impact outcomes. The Area Deprivation Index (ADI), a composite of seventeen SDoH factors, has been correlated with poorer outcomes. We aimed to compare outcomes and treatment access for glioblastoma, a universally fatal malignant brain tumor, in patients more (ADI 34–100%) versus less disadvantaged (ADI 0–33%). Methods A 5-year retrospective study of Rhode Island Hospital and Mayo Clinic databases was conducted from 2012 to 2017 for patients ≥ 18 years with glioblastoma. Patient addresses were matched to ADI percentiles and grouped into more (top 66% ADI) and less disadvantaged. Adjusted multivariable regressions were used to compare outcomes between groups. Results A total of 434 patients met inclusion; 92.9% were insured, 56.2% were more disadvantaged (n = 244), and the more disadvantaged cohort was younger on average (62 years). After adjustment, the more disadvantaged group had decreased odds of receiving gross total resection (adjusted odds ratio (aOR) 0.43, 95% CI [0.27–0.68]; p < 0.001). This cohort also had decreased odds of undergoing chemotherapy (aOR 0.51[0.26–0.98]), radiation (aOR 0.39[0.20–0.77]), chemoradiation (aOR 0.42[0.23–0.77]), tumor-treating fields (aOR 0.39[0.16–0.93]), and clinical trial participation (aOR 0.47[0.25–0.91]). No differences in length of survival or postoperative Karnofsky Performance Status Scale were observed. Conclusion More disadvantaged glioblastoma patients had decreased odds of receiving gross total resection. They also exhibited decreased odds of receiving standard of care like chemoradiation as well as participating in a clinical trial, compared to the less disadvantaged group. More research is needed to identify modifiable SDoH barriers to post-operative treatment in disadvantaged patients with glioblastoma.Keywords
This publication has 49 references indexed in Scilit:
- Extent of Resection of Glioblastoma Revisited: Personalized Survival Modeling Facilitates More Accurate Survival Prediction and Supports a Maximum-Safe-Resection Approach to SurgeryJournal of Clinical Oncology, 2014
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Postoperative Mortality After Surgery for Brain Tumors by Patient Insurance Status in the United StatesArchives of Surgery, 2012
- Improved survival time trends for glioblastoma using the SEER 17 population-based registriesJournal of Neuro-Oncology, 2011
- Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Neuro-Oncology, 2011
- Disparities in Access to Neuro-oncologic Care in the United StatesArchives of Surgery, 2010
- Disparities in Access to Pediatric Neurooncological Surgery in the United StatesPediatrics, 2009
- Predictors of access to pituitary tumor resection in the United States, 1988–2005European Journal of Endocrinology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005